World
ALK’s tree pollen tablet (ITULAZAX®) now recommended by NICE for use in the UK health system
ALK (ALKB:DC / OMX: ALK B) today announced that the National Institute for Health and Care Excellence (NICE) has recommended the use of the company’s tree pollen tablet ITULAZAX® for the treatment in adults. The recommendation allows for patients to gain access to ITULAZAX® through the National Health Service (NHS) systems in England, Wales, and Northern Ireland by making it eligible for general reimbursement. The recommendation of ITULAZAX® is another significant milestone for ALK, marking the
About this update from Alk-abello A/s Class B
[{"type":"image","alt":"ALK Abello","displaySize":"","headline":null,"caption":"ALK Abello","className":"","disableSlideshowImg":false,"size":{"original":{"width":142,"height":39,"url":"https://media.zenfs.com/en/globenewswire.com/a84b59e43cd2eb1b97add5c2b0dfe2b1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/gfL7lNIX7z950ZiB3KRYoQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTU4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/a84b59e43cd2eb1b97add5c2b0dfe2b1","width":142,"height":39}},"lazy":false},{"type":"text","content":"ALK (ALKB:DC / OMX: ALK B) today announced that the National Institute for Health and Care Excellence (NICE) has recommended the use of the company’s tree pollen tablet ITULAZAX® for the treatment in adults. The recommendation allows for patients to gain access to ITULAZAX® through the National Health Service (NHS) systems in England, Wales, and Northern Ireland by making it eligible for general reimbursement.","length":418,"tagName":"p"},{"type":"text","content":"The recommendation of ITULAZAX® is another significant milestone for ALK, marking the second NICE approval of ALK’s sublingual allergy immunotherapy (AIT) products received in 2025. Being the first-ever of their kinds to become widely accessible through the National Health Service (NHS) systems, ACARIZAX® (final approval obtained in March 2025) and ITULAZAX® are now available treatment options to address the significant underutilisation of AIT in the UK compared to other European countries.","length":496,"tagName":"p"},{"type":"text","content":"ALK’s Executive Vice President of Commercial Operations, Søren Niegel, says: “Today’s approval emphasises a remarkable achievement by ALK with now two of our sublingual allergy immunotherapy tablets being recommended by NICE within less than six months. We appreciate the endorsement from a highly respected institute like NICE which improves the treatment accessibility for patients impacted by allergy”. ","length":406,"tagName":"p"},{"type":"text","content":"Scientists warn that this year's tree pollen season has started early due to warm weather, leading to higher pollen counts. This is bad news for the approximately 16 million people who are affected by hay fever in the UK, and while many manage symptoms with over-the-counter medicines, the consequences can be more challenging for the 4 million people...